A Phase I/II Trial of Rituximab, Bendamustine, and Obatoclax in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma.

Trial Profile

A Phase I/II Trial of Rituximab, Bendamustine, and Obatoclax in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma.

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2013

At a glance

  • Drugs Obatoclax (Primary) ; Bendamustine; Rituximab
  • Indications B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Jun 2013 Status changed from suspended to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 16 Jan 2013 Status changed from completed to suspended as reported by ClinicalTrials.gov.
    • 25 Apr 2012 Actual end date Apr 2012 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top